الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Purpose: to compare the efficacy, safety, and tolerability of intralesional Measles Mumps Rubella (MMR) vaccine versus intralesional and intradermal purified protein derivative (PPD) in treatment of female anogenital wart. Materials and methods : This is a randomized clinical trial that included 69 female patients with anogenital warts aged above 18 years old divided into three egual groups. Patients in group 1 received intralesional MMR at a dose of (0.2 ml). Patients in group 2 received intralesional PPD (0.2 ml). Patients in group 3 received intradermal PPD (0.2 ml). In all groups, insulin syringe was used to inject the largest wart. Injections were repeated for all patients into the same lesion (largest wart) every 2 weeks until clearance or a maximum of 5 treatment session. Results: Overall complete response showed higher complete response rates in the MMR group with complete clearance of all warts in 78.3 % of patients. But in intralesional injection of PPD complete responses was in 69.6% of patients and in intradermal injection of PPD complete clearance of all warts was in 56.5% of patients. Conclusions: Both intralesional MMR, intralesional PPD and intradermal PPD are effective in treatment of anogenital warts with lower recurrence rates and higher safety profile of MMR. . Keywords MMR, PPD , anogenital warts